ClinicalTrials.gg
CompletedNCT03348046PASSRRAUpdated Mar 4, 2020

Safety Study of Remsima® (Infliximab) in Rheumatoid Arthritis Patients in Jordan

An observational study in Rheumatoid Arthritis, sponsored by Hikma Pharmaceuticals LLC. Completed at 2 sites in Jordan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-04.

Sponsored by Hikma Pharmaceuticals LLC · Observational

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
22
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this observational study is to assess the safety and effectiveness of biosimilar Infliximab in patients with rheumatoid arthritis(RA) in Jordan where no visits or intervention(s) additional to the daily practice will be performed

Read the detailed description

A multi-center, observational, prospective, cohort study to assess the safety and effectiveness of biosimilar Infliximab (Remsima®) in patients with rheumatoid arthritis in Jordan. Biologic naïve patients will receive Remsima® in accordance with standard medical care and the approved label and will be followed over a period of 34 weeks (8.5 months). Outcomes including occurrence of adverse events (AEs), mean changes in disease activity and health assessment in each cohort will be measured and compared

02

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Infliximab
  • Remsima
  • Biosimilar
  • Autoimmune Disease
  • Rheumatoid Arthritis
  • Cohort Study
  • Disease modifying anti-rheumatic drugs
  • Tumor necrosis factor-alpha inhibitors
03

In context

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

This study's enrollment of 22 is below the median of 176 across 1,017 observational studies indexed under Arthritis, Rheumatoid.

Browse Arthritis, Rheumatoid studies →

Lead sponsor

Hikma Pharmaceuticals LLC is the lead sponsor of 14 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients will be recruited from rheumatology outpatient clinics of 2 hospitals in Jordan

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (age ≥18 years)
  • Biologic naïve patients with active RA diagnosed according to the revised 1987 American College of Rheumatology (ACR) (Arnett et al. 1988) or 2010 ACR / European League Against Rheumatism (EULAR) Rheumatoid Arthritis classification criteria (Aletaha et al. 2010)
  • Patients should be receiving a stable dose Methotrexate (MTX) for at least 3 months prior to enrolment, and still have active disease defined as erythrocyte sedimentation rate (ESR) ≥28 mm/h and swollen and tender joints ≥ 6
  • Absence of tuberculosis demonstrated by negative chest X-ray

Exclusion criteria

Exclusion Criteria:

  • Patient \<18 years
  • Previous treatment with biologics
  • Patients who meet any of the to the administration of infliximab
  • Previous or concurrent
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
22 participants (actual)
Patient registry
No

Interventions

  • A vial containing powder for concentrate for solution for infusion. Each vial contains: Infliximab 100 mg

    Also known as: Remsima®

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) to Remsima®

    Rate of AEs leading to permanent treatment discontinuation and rate of clinically relevant changes in laboratory tests will be calculated

    Time frame: 8.5 months

Secondary outcomes

  1. Mean changes in disease activity scores (DAS28)- Number of swollen joints

    The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured. The number of swollen joints will be assessed.

    Time frame: 8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses

  2. Mean changes in disease activity scores (DAS28)-Number of tender joints

    The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured. The number of tender joints will be assessed.

    Time frame: 8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses

  3. Mean changes in disease activity scores (DAS28)-ESR (Erythrocyte Sedimentation Rate)

    The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured. ESR (Erythrocyte Sedimentation Rate) will be measured in mm/hr.

    Time frame: 8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses

  4. Mean changes in disease activity scores (DAS28)- Global assessment of disease activity on a 100 mm Visual Analogue Scale (VAS)

    The Disease Activity Score (DAS) measures the disease activity in patients with Rheumatoid Arthritis (RA). DAS28 is a validated simplified tool in which twenty-eight joints are measured. Patients will be asked to make a global assessment of disease activity on a 100 mm Visual Analogue Scale (VAS) measured by units on scale. Number of swollen and tender joints, Erythrocyte Sedimentation Rate and global assessment of disease activity on a 100 mm Visual Analogue Scale (VAS) are then fed into a complex mathematical formula to produce the overall disease activity score. The DAS28 provides a number on a scale from 0 to 10 indicating the current activity of the RA of the patient. A DAS28 above 5.1 means high disease activity whereas a DAS28 below 3.2 indicates low disease activity. Remission is achieved by a DAS28 lower than 2.6.

    Time frame: 8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses

  5. Mean changes in Disability Index of the Health Assessment Questionnaire (HAQ-DI)

    The Health assessment questionnaire disability index (HAQ-DI) is a questionnaire for the assessment of Rheumatoid Arthritis. The reported data from patients include the amount of difficulty they have in performing some of their activities. Each question asks on a scale ranging from 0 to 3 if the categories can be performed without any difficulty (scale 0) up to cannot be done at all (scale 3).

    Time frame: 8.5 months, changes between baseline and last visit will be compared between visits using repeated measure analyses

07

Study locations

2 sites
  • Prince Hamza Hospital
    Amman, Jordan
  • Jordan University of Science and Technology- King Abdallah University Hospital
    Irbid, Jordan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2017 to primary completion in Apr 2019, 24 months.

Of 155 industry-sponsored observational studies under Arthritis, Rheumatoid, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 113. This study's 24 months is below that.

Counting every sponsor, half of 391 studies reached it within 50 months; a quarter within 25 and three quarters within 113.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2017
First posted
Nov 20, 2017
StartActual
Mar 23, 2017
Primary completionActual
Apr 14, 2019
CompletionActual
Apr 14, 2019
Last update
Mar 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03348046
Collaborators
Syneos Health
Responsible party
Sponsor
First posted
Nov 20, 2017
Start date
Mar 23, 2017
Primary completion
Apr 14, 2019
Completion
Apr 14, 2019
Last update
Mar 4, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion